Your source for the latest medtech news from AdvaMed® and our members.
BlueWind Medical, Ltd., AdvaMed® member and developer of the innovative RENOVA iStim™ implantable tibial neuromodulation (iTNM) device for treatment of Overactive Bladder, today announced the addition of Charles F. (“Chuck”)…
Following the release of the House Energy and Commerce Committee’s FDA User Fees Legislative Package, the Advanced Medical Technology Association® (AdvaMed®) released this statement from President and CEO Scott Whitaker.
Scott Whitaker, President and CEO of AdvaMed®, led a meeting of medtech CEOs and leaders with Secretary of Commerce Gina Raimondo to discuss semiconductor chip supply chain issues impacting the…
BlueWind Medical, Ltd., AdvaMed® member and developer of the innovative RENOVA iStim™ implantable tibial neuromodulation (iTNM) device for treatment of Overactive Bladder, today announced the addition of Charles F. (“Chuck”)…
If you have media inquiries, please contact:
Jim Jeffries, Senior Vice President, Public Affairs, 202-434-7242
The Advanced Medical Technology Association® (AdvaMed®) recently responded to the Department of Commerce’s request for information on ways to support a strong domestic semiconductor industry.
AdvaMed® member Cook Medical’s Zenith® Thoraco+ Endovascular System (Thoraco+) has received Breakthrough Device Designation from the US Food and Drug Administration (FDA).
AdvaMed® welcomes the opportunity to testify before a key congressional committee on the fifth reauthorization of the Medical Device User Fee Amendments (MDUFA).
The Food and Drug Administration (FDA) has released its draft commitment letter on the fifth reauthorization of the Medical Device User Fee Amendments (MDUFA), reflecting an agreement between the agency and the…
Brought to you by AdvaMed®, Medtech POV with Scott Whitaker is a podcast that covers the intersection of medtech and policy from every perspective.
AdvaMed®, the world’s largest trade organization representing medical technology manufacturers, today announced that its board of directors has unanimously approved revisions to the AdvaMed® Code of Ethics on Interactions with Health Care Professionals.